Mesoblast (MESO) Competitors

$15.08 +0.35 (+2.38%)

Closing price 04:00 PM Eastern

Extended Trading

$14.98 -0.11 (-0.70%)

As of 04:23 PM Eastern

MESO vs. KYMR, QGEN, TGTX, MIRM, and SYRE

Should you buy Mesoblast stock or one of its competitors? MarketBeat compares Mesoblast with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mesoblast include Kymera Therapeutics (KYMR), Qiagen (QGEN), TG Therapeutics (TGTX), Mirum Pharmaceuticals (MIRM), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Mesoblast compare to Kymera Therapeutics?

Mesoblast (NASDAQ:MESO) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Kymera Therapeutics has a consensus target price of $118.10, suggesting a potential upside of 39.76%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Mesoblast has higher revenue and earnings than Kymera Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$65.38M	29.86	-$102.14M	-$0.54	N/A
Kymera Therapeutics	$39.21M	177.28	-$311.35M	-$3.57	N/A

Mesoblast has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.06, indicating that its share price is 106% more volatile than the broader market.

Mesoblast has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Mesoblast's return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

In the previous week, Kymera Therapeutics had 6 more articles in the media than Mesoblast. MarketBeat recorded 8 mentions for Kymera Therapeutics and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Kymera Therapeutics' score of 0.32 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.4% of Mesoblast shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Mesoblast beats Kymera Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Mesoblast compare to Qiagen?

Qiagen (NYSE:QGEN) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Qiagen has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.10B	3.27	$424.88M	$1.91	17.44
Mesoblast	$65.38M	29.86	-$102.14M	-$0.54	N/A

Qiagen presently has a consensus price target of $46.38, suggesting a potential upside of 39.25%. Given Qiagen's stronger consensus rating and higher probable upside, research analysts plainly believe Qiagen is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market.

In the previous week, Qiagen had 11 more articles in the media than Mesoblast. MarketBeat recorded 13 mentions for Qiagen and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Qiagen's score of 0.23 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a net margin of 19.16% compared to Mesoblast's net margin of 0.00%. Qiagen's return on equity of 14.40% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Mesoblast	N/A	N/A	N/A

Summary

Qiagen beats Mesoblast on 12 of the 16 factors compared between the two stocks.

How does Mesoblast compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

TG Therapeutics has a net margin of 65.95% compared to Mesoblast's net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Mesoblast	N/A	N/A	N/A

TG Therapeutics has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$700.35M	8.92	$447.18M	$2.86	14.26
Mesoblast	$65.38M	29.86	-$102.14M	-$0.54	N/A

TG Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

TG Therapeutics currently has a consensus price target of $52.50, suggesting a potential upside of 28.71%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TG Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, TG Therapeutics had 11 more articles in the media than Mesoblast. MarketBeat recorded 13 mentions for TG Therapeutics and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat TG Therapeutics' score of 0.70 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Mesoblast on 12 of the 16 factors compared between the two stocks.

How does Mesoblast compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Mirum Pharmaceuticals has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.03	-$23.36M	-$13.61	N/A
Mesoblast	$65.38M	29.86	-$102.14M	-$0.54	N/A

In the previous week, Mirum Pharmaceuticals had 22 more articles in the media than Mesoblast. MarketBeat recorded 24 mentions for Mirum Pharmaceuticals and 2 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Mirum Pharmaceuticals' score of 0.67 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mesoblast has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mesoblast's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Mesoblast	N/A	N/A	N/A

Mirum Pharmaceuticals has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.09, meaning that its share price is 109% more volatile than the broader market.

Mirum Pharmaceuticals currently has a consensus target price of $136.42, indicating a potential upside of 22.47%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

1.4% of Mesoblast shares are owned by institutional investors. 14.4% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Mesoblast beats Mirum Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Mesoblast compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

In the previous week, Spyre Therapeutics had 8 more articles in the media than Mesoblast. MarketBeat recorded 10 mentions for Spyre Therapeutics and 2 mentions for Mesoblast. Spyre Therapeutics' average media sentiment score of 0.96 beat Mesoblast's score of 0.93 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics presently has a consensus target price of $90.25, suggesting a potential upside of 19.30%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Spyre Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Mesoblast's return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Mesoblast	N/A	N/A	N/A

Spyre Therapeutics has a beta of 3.12, meaning that its stock price is 212% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Mesoblast has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$2.08	N/A
Mesoblast	$65.38M	29.86	-$102.14M	-$0.54	N/A

Summary

Spyre Therapeutics beats Mesoblast on 8 of the 15 factors compared between the two stocks.

Get Mesoblast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MESO vs. The Competition

Export

Metric	Mesoblast	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.95B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-27.93	18.81	20.87	25.58
Price / Sales	29.86	181.67	521.63	63.56
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	3.23	6.74	9.86	6.70
Net Income	-$102.14M	$24.11M	$3.55B	$333.77M
7 Day Performance	1.89%	0.07%	-0.32%	0.45%
1 Month Performance	3.22%	0.84%	1.34%	4.06%
1 Year Performance	30.68%	78.10%	41.03%	36.21%

Mesoblast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MESO Mesoblast	1.4765 of 5 stars	$15.08 +2.4%	N/A	+23.7%	$1.95B	$65.38M	N/A	80
KYMR Kymera Therapeutics	2.3817 of 5 stars	$84.10 -2.3%	$118.10 +40.4%	+174.9%	$7.08B	$39.21M	N/A	170	Insider Trade
QGEN Qiagen	4.5752 of 5 stars	$32.63 -1.3%	$46.38 +42.1%	-26.1%	$6.81B	$2.09B	17.04	5,654	Earnings Report Dividend Increase Analyst Downgrade
TGTX TG Therapeutics	4.304 of 5 stars	$43.14 +0.7%	$52.50 +21.7%	+27.8%	$6.56B	$616.29M	15.08	290
MIRM Mirum Pharmaceuticals	2.4124 of 5 stars	$106.17 -0.9%	$136.42 +28.5%	+141.1%	$6.53B	$521.31M	N/A	140	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MESO) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mesoblast (MESO) Competitors

MESO vs. KYMR, QGEN, TGTX, MIRM, and SYRE

How does Mesoblast compare to Kymera Therapeutics?

Summary

How does Mesoblast compare to Qiagen?

Summary

How does Mesoblast compare to TG Therapeutics?

Summary

How does Mesoblast compare to Mirum Pharmaceuticals?

Summary

How does Mesoblast compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mesoblast (MESO) Competitors

MESO vs. KYMR, QGEN, TGTX, MIRM, and SYRE

How does Mesoblast compare to Kymera Therapeutics?

Do analysts recommend MESO or KYMR?

Which has better valuation and earnings, MESO or KYMR?

Which has more volatility & risk, MESO or KYMR?

Is MESO or KYMR more profitable?

Does the media prefer MESO or KYMR?

Do institutionals & insiders hold more shares of MESO or KYMR?

Summary

How does Mesoblast compare to Qiagen?

Do insiders and institutionals hold more shares of QGEN or MESO?

Which has preferable valuation & earnings, QGEN or MESO?

Do analysts recommend QGEN or MESO?

Which has more risk & volatility, QGEN or MESO?

Does the media prefer QGEN or MESO?

Is QGEN or MESO more profitable?

Summary

How does Mesoblast compare to TG Therapeutics?

Is TGTX or MESO more profitable?

Which has higher earnings & valuation, TGTX or MESO?

Which has more risk and volatility, TGTX or MESO?

Do institutionals and insiders hold more shares of TGTX or MESO?

Do analysts recommend TGTX or MESO?

Does the media favor TGTX or MESO?

Summary

How does Mesoblast compare to Mirum Pharmaceuticals?

Which has preferable earnings & valuation, MIRM or MESO?

Does the media prefer MIRM or MESO?

Is MIRM or MESO more profitable?

Which has more risk and volatility, MIRM or MESO?

Do analysts prefer MIRM or MESO?

Do institutionals and insiders believe in MIRM or MESO?

Summary

How does Mesoblast compare to Spyre Therapeutics?

Does the media favor SYRE or MESO?

Do analysts recommend SYRE or MESO?

Is SYRE or MESO more profitable?

Which has more risk & volatility, SYRE or MESO?

Do institutionals and insiders hold more shares of SYRE or MESO?

Which has higher valuation and earnings, SYRE or MESO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools